AstraZeneca imegundulika kutibu cancer ya mapafu katika stage za mwanzo

AstraZeneca imegundulika kutibu cancer ya mapafu katika stage za mwanzo

Sky Eclat said:

At the forefront of lung cancer treatment

To improve lung cancer outcomes, we are prioritising research, increasing early screening and diagnosis and addressing unmet needs at all disease stages.
www.astrazeneca.com www.astrazeneca.com

Lung cancer is the leading cause of cancer death worldwide, accounting for about 2.2 million patients diagnosed and 1.8 million deaths each year.1 The two main types of lung cancer are non-small cell lung cancer (NSCLC), which represents 80-85% of patients, and small cell lung cancer (SCLC), the more aggressive and fast-growing cancer type representing about 15% of patients.2-3​

The earlier we can detect and treat lung cancer, the closer we are to cure.4-5 Unfortunately, early diagnosis is not always a reality.6​

In many cases, lung cancer goes undetected until it is in advanced stages or the cancer comes back after initial treatment.6 For these patients who experience recurrence, outcomes are especially poor.4-5 To meaningfully improve outcomes, we are prioritising lung cancer research to increase early screening and diagnosis and address the significant unmet need for treatments at every stage of the disease continuum.​



Our portfolio of approved and potential new medicines in late-stage development spans different histologies, several stages of disease, lines of therapy and modes of action.7 Our approach is driven by precision medicine, using groundbreaking science to further our understanding of lung cancer and deliver medicines matched to the patients who can best benefit from them. This includes thinking differently about the underlying biology of lung cancer, from early stages – where we aim to help patients live longer and cancer-free – to late stages, where we look to meaningfully extend survival.​

Targeting Biomarkers and Resistance Mechanisms​



By focusing on the unique properties of a tumour and looking in new places – beyond traditional classifications – we are defining new biomarkers and therapeutic targets to transform the way people with lung cancer are diagnosed and treated.​

Click to expand...
Mimi ninayo dawa ya kutibu Cancer ya Mapafu kwa stage zake zote 4.
 
Njia salama ya kutibu Cancer ni kukata sehemu yenye Cancer. Hizo njia zingine zinasababisha matatizo Cancer kurudi tena kwa kasi zaidi.
 
Sky Eclat said:

At the forefront of lung cancer treatment

To improve lung cancer outcomes, we are prioritising research, increasing early screening and diagnosis and addressing unmet needs at all disease stages.
www.astrazeneca.com www.astrazeneca.com

Lung cancer is the leading cause of cancer death worldwide, accounting for about 2.2 million patients diagnosed and 1.8 million deaths each year.1 The two main types of lung cancer are non-small cell lung cancer (NSCLC), which represents 80-85% of patients, and small cell lung cancer (SCLC), the more aggressive and fast-growing cancer type representing about 15% of patients.2-3​

The earlier we can detect and treat lung cancer, the closer we are to cure.4-5 Unfortunately, early diagnosis is not always a reality.6​

In many cases, lung cancer goes undetected until it is in advanced stages or the cancer comes back after initial treatment.6 For these patients who experience recurrence, outcomes are especially poor.4-5 To meaningfully improve outcomes, we are prioritising lung cancer research to increase early screening and diagnosis and address the significant unmet need for treatments at every stage of the disease continuum.​



Our portfolio of approved and potential new medicines in late-stage development spans different histologies, several stages of disease, lines of therapy and modes of action.7 Our approach is driven by precision medicine, using groundbreaking science to further our understanding of lung cancer and deliver medicines matched to the patients who can best benefit from them. This includes thinking differently about the underlying biology of lung cancer, from early stages – where we aim to help patients live longer and cancer-free – to late stages, where we look to meaningfully extend survival.​

Targeting Biomarkers and Resistance Mechanisms​



By focusing on the unique properties of a tumour and looking in new places – beyond traditional classifications – we are defining new biomarkers and therapeutic targets to transform the way people with lung cancer are diagnosed and treated.​

Click to expand...
Tuandikie kwa lugha yetu adhimu ya kiswahili
 
Sky Eclat said:
Msukuma ameanza kuhoji msimamo wa maprofesa ambao mpaka March mwaka huu wakisema hakuna Covid Tanzania na sasa hivi wanahamasisha chanjo.
Click to expand...
Msukuma mpumbavu yeye chanjo haimhusu kwa sababu hana uwezo wa kusafiri njee ya nchi yeye biashara zake ni za hapahapa bongi
 
chilubi said:
Post nzima sikuona mahala paliposema kuwa chanjo ya covid inaweza kutibu cance ya mapafu. labda kama kuna mstari sijauona vizuri. Astrazaneca ni kampuni sio chanjo ya covid.
Click to expand...

Oncology – AstraZeneca - Redefining Cancer Care

Our Oncology strategy is built with one goal in mind – to push the boundaries of science to transform the lives of patients living with cancer. Learn more
www.astrazeneca.com www.astrazeneca.com
 
Sky Eclat said:

Oncology – AstraZeneca - Redefining Cancer Care

Our Oncology strategy is built with one goal in mind – to push the boundaries of science to transform the lives of patients living with cancer. Learn more
www.astrazeneca.com www.astrazeneca.com
Click to expand...
Astrazaneca sio chanjo ya Covid 19, hilo ni jina la kampuni, kama ukisikia kuna chanjo ya Johnson and Johnson, ni jina la kampuni.

Kwenye link ulioleta sijaona mahala paliposema kuwa chanjo ya covid inafaida ya ziada ya kutibu cancer ya mapafu
 
You must log in or register to reply here.

Our Community

Regional Communities

Back
Top Bottom
Menu
Forums
New posts
Log in
Register